Share on StockTwits

Equities research analysts at SunTrust began coverage on shares of Pharmacyclics (NASDAQ:PCYC) in a research note issued to investors on Thursday. The firm set a “neutral” rating on the stock.

Several other analysts have also recently commented on the stock. Analysts at William Blair raised their price target on shares of Pharmacyclics from $150.00 to $180.00 in a research note on Tuesday, August 5th. They now have an “outperform” rating on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $180.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Pharmacyclics in a research note on Friday, August 1st. They now have a $152.00 price target on the stock, up previously from $150.00. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $155.33.

In other Pharmacyclics news, COO Maky Zanganeh sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $121.75, for a total value of $1,461,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Pharmacyclics (NASDAQ:PCYC) traded down 2.97% on Thursday, hitting $119.30. 668,812 shares of the company’s stock traded hands. Pharmacyclics has a 52 week low of $82.51 and a 52 week high of $154.89. The stock has a 50-day moving average of $115.5 and a 200-day moving average of $107.1. The company has a market cap of $8.980 billion and a P/E ratio of 109.87.

Pharmacyclics (NASDAQ:PCYC) last announced its earnings results on Thursday, July 31st. The company reported ($0.26) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.23) by $0.03. The company had revenue of $113.00 million for the quarter, compared to the consensus estimate of $95.88 million. During the same quarter in the prior year, the company posted $0.25 earnings per share. The company’s quarterly revenue was up 106.6% on a year-over-year basis. On average, analysts predict that Pharmacyclics will post $0.36 earnings per share for the current fiscal year.

Pharmacyclics, Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.